Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology

Volumn 73, Issue 15, 2009, Pages 1227-1233

  Miller, R G ^a   Jackson, C E ^b   Kasarskis, E J ^c   England, J D ^d   Forshew, D ^a   Johnston, W ^e   Kalra, S ^e   Katz, J S ^a   Mitsumoto, H ^f   Rosenfeld, J ^g   Shoesmith, C ^h   Strong, M J ^h   Woolley, S C ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f NEUROLOGICAL INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; ATROPINE; BACLOFEN; BENZATROPINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; DANTROLENE; DEXTROMETHORPHAN; GABAPENTIN; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; LORAZEPAM; METOPROLOL; OPIATE; OXYGEN; PLACEBO; PROPRANOLOL; QUINIDINE; QUININE; RILUZOLE; TIZANIDINE; TRIHEXYPHENIDYL;

AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; ARTICLE; ARTIFICIAL VENTILATION; ASTHENIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DIZZINESS; DRUG WITHDRAWAL; DYSARTHRIA; DYSPNEA; ERYTHEMA; EVIDENCE BASED PRACTICE; EXERCISE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HOSPICE CARE; HUMAN; HYPERSALIVATION; INSOMNIA; INTERPERSONAL COMMUNICATION; LOW ENERGY RADIATION; MUSCLE CRAMP; NAUSEA; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PAIN; PALLIATIVE THERAPY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PSEUDOBULBAR PALSY; QUALITY OF LIFE; SALIVARY GLAND; SCREENING; SOMNOLENCE; SORE THROAT; SPASTICITY; SURVIVAL; SURVIVAL TIME; SYMPTOM; SYSTEMATIC REVIEW; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

AMYOTROPHIC LATERAL SCLEROSIS; COGNITION DISORDERS; DEMENTIA; EVIDENCE-BASED MEDICINE; FATIGUE; HUMANS; MUSCLE CRAMP; PALLIATIVE CARE; PATIENT CARE TEAM; PSEUDOBULBAR PALSY; SIALORRHEA; TERMINAL CARE; TRUTH DISCLOSURE;

EID: 70350138259     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181bc01a4     Document Type: Article

References (40)

1. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52:1311-1323.
2. McCluskey L, Casarett D, Siderowf A. Breaking the news: a survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:131-135.
3. Borasio GD, Sloan R, Pongratz DE. Breaking the news in amyo-trophic lateral sclerosis. J Neurol Sci 1998;160(suppl 1):S127- 133.
4. Numico G, Anfossi M, Bertelli G, et al. The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer. Ann Oncol 2009;20:941-945.
5. Bradley WG, Anderson F, Gowda N, Miller RG. Changes in the management of ALS since the publication of the AAN ALS practice parameter 1999. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:240-244.
6. Chio A, Bottacchi E, Buffa C, Mutani R, Mora G. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neuro-surg Psychiatry 2006;77:948-950.
7. Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-215.
8. Sorenson EJ, Mandrekar J, Crum B, Stevens JC. Effect of referral bias on assessing survival in ALS. Neurology 2007;68:600-602.
9. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effects of a multidisciplinary ALS clinic on survival. J Neu-rol Neurosurg Psychiatry 2003;74:1258-1261.
10. Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidis-ciplinary ALS care improves quality of life in patients with ALS. Neurology 2005;65:1264-1267.
11. Zoccolella S, Beghi E, Palagano G, et al. ALS multidisci-plinary clinic and survival : Results from a population-based study in Southern Italy. J Neurol 2007;254:1107-1112. (Pubitemid 47353403)
12. Bradley WG, Anderson F, Bromberg M, et al. Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. Neurology 2001;57:500-504.
13. Levitsky G. Pharmacological therapy of sialorrhea in patients with motor neuron disease. ZH Neurol Psikhiar Im SS Kovsakova 2005;105:19-22.
14. Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2008;39:137-143.
15. Harriman M, Morrison M, Hay J, Revonta M, Eisen A, Lentle B. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. J Otolaryngol 2001; 30:242-245.
16. Andersen PM, Gronberg H, Franze L, Funegard U. External radiation of the parotid glands significantly reduces drooling in patients with motor neuron disease with bulbar paresis. J Neurol Sci 2001;191:111-114.
17. Molloy L. Treatment of sialorrhea in patients with Parkinson?s disease: best current evidence. Curr Opin Neurol 2007;20:493-498.
18. McCullagh S, Moore M, Gawel M, Feinstein A. Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction. J Neurol Sci 1999;169:43-48.
19. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quin-idine: a randomized trial. Neurology 2004;63:1364-1370.
20. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Ri-luzole Study Group N Engl J Med 1994;330:585-591.
21. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Mein-inger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-1431.
22. Miller RG, Moore DH, 2nd, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotro-phic lateral sclerosis. Neurology 2001;56:843-848.
23. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18.
24. Forshew DA, Bromberg MB. A survey of clinicians? practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:258-263.
25. Drug products withdrawn from sale for reasons other than safety or effectiveness: quinine-containing drug products; enforcement action dates. Federal Register 2006 Dec 15; 71(241):75557-75560.
26. Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyo-trophic lateral sclerosis. J Neurol Sci 2001;191:133-137.
27. Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112:649-660.
28. Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002;9 (suppl 1):30-34; discussion 53-61.
29. Kurt A, Nijboer F, Matuz T, Kubler A. Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs 2007;21:279-291.
30. Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology 2005;65:62-67.
31. Andersen PM, Borasio GD, Dengler R, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 2005;12:921-938.
32. Hetta J, Jansson I. Sleep in patients with amyotrophic lateral sclerosis. J Neurol 1997;244:S7-S9.
33. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
34. Poloni M, Capitani E, Mazzini L, Ceroni M. Neuropsy-chological measures in amyotrophic lateral sclerosis and their relationship with CT scan-assessed cerebral atrophy. Acta Neurol Scand 1986;74:257-260.
35. Frank B, Haas J, Heinze HJ, Stark E, Munte TF. Relation of neuropsychological and magnetic resonance findings in amyotrophic lateral sclerosis: evidence for subgroups. Clin Neurol Neurosurg 1997;99:79-86.
36. Rakowicz WP, Hodges JR. Dementia and aphasia in motor neuron disease: an underrecognised association? J Neu-rol Neurosurg Psychiatry 1998;65:881-889.
37. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005;65:586-590.
38. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Ol-ney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094-1097.
39. Murphy JM, Henry RG, Langmore S, Kramer JH, Miller BL, Lomen-Hoerth C. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol 2007;64:530-534.
40. Robinson KM, Lacey SC, Grugan P, Glosser G, Grossman M, McCluskey LF. Cognitive functioning in sporadic amyotrophic lateral sclerosis: a six month longitudinal study. J Neurol Neurosurg Psychiatry 2006;77:668-670.